Teasing out the overall survival benefit with adjustment for treatment switching to other therapies

08/01/2019
by   Yuqing Xu, et al.
0

In oncology clinical trials, characterizing the long-term overall survival (OS) benefit for an experimental drug or treatment regimen (experimental group) is often unobservable if some patients in the control group switch to drugs in the experimental group and/or other cancer treatments after disease progression. A key question often raised by payers and reimbursement agencies is how to estimate the true benefit of the experimental drug group on overall survival that would have been estimated if there were no treatment switches. Several commonly used statistical methods are available to estimate overall survival benefit while adjusting for treatment switching, ranging from naive exclusion or censoring approaches to more advanced methods including inverse probability of censoring weighting (IPCW), iterative parameter estimation (IPE) algorithm or rank-preserving structural failure time models (RPSFTM). However, many clinical trials now have patients switching to different treatment regimens other than the test drugs, and the existing methods cannot handle more complicated scenarios. To address this challenge, we propose two additional methods: stratified RPSFTM and random-forest-based prediction. A simulation study is conducted to assess the properties of the existing methods along with the two newly proposed approaches.

READ FULL TEXT

page 14

page 15

page 16

research
05/19/2020

A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching

In confirmatory cancer clinical trials, overall survival (OS) is normall...
research
03/10/2023

Adjusting for time-varying treatment switches in randomized clinical trials: the danger of extrapolation and how to avoid it

When choosing estimands and estimators in randomized clinical trials, ca...
research
11/21/2019

Mixture survival models methodology: an application to cancer immunotherapy assessment in clinical trials

Progress in immunotherapy revolutionized the treatment landscape for adv...
research
08/08/2023

A Dual Cox Model Theory And Its Applications In Oncology

Given the prominence of targeted therapy and immunotherapy in cancer tre...
research
11/18/2020

Assessing contribution of treatment phases through tipping point analyses using rank preserving structural failure time models

In clinical trials, an experimental treatment is sometimes added on to a...
research
12/20/2021

The Predictive Individual Effect for Survival Data

The call for patient-focused drug development is loud and clear, as expr...

Please sign up or login with your details

Forgot password? Click here to reset